...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
AGORACOM NEWS FLASH

Dear Agoracom Family,

I want to thank all of you for your patience with us over the past 48 hours and apologize for what was admittedly a botched launch of our new site.

As you can see, we have reverted back to the previous version of the site while we address multiple forum functionality flaws that inexplicably made their way into the launch.

To this end:

1.We have identified 8 fundamental but easily fixable flaws that will be corrected in the coming week, so that you can continue to use the forums exactly as you've been accustomed to.

2.Additionally we will also be implementing a couple of design improvements to "tighten up" the look and feel of the forums.

Sincerely,

George et al

Message: Re: Private placement one million plus units for US$2, half wt exercisable at US3, good for 3 years

Hi Dutchfella, 

Feb 19,  you must have a premonition, as Zenith just did a small PP, did get some??

Below is part of what you stated

Despite the $5 MM milestone payment, ZEN, like all Junior biotechs, wil be interested in adding to their cash reserves to cover expenses because science is expensive. I would not be surprised to see another financing not too far down the road. Will they wait for some good news to boost the offering price above the last US$2 sale or will they do the sale pre news to give more US$2 shares to "hint hint nudge nudge wink wink" family, friends, partners and past big investors?

I think i will contact them and ask to be put on their investor list for the next financing --- just in case. "Say no more, say no more!"

 

 

 

Share
New Message
Please login to post a reply